AgriMetis, LLC is pleased to announce that Dr. Andrew Plant joined the AgriMetis team as Chief Technology Officer (CTO) in July 2019.
LUTHERVILLE, MD – August 12, 2019 – AgriMetis, LLC is pleased to announce that Dr. Andrew Plant joined the AgriMetis team as Chief Technology Officer (CTO) in July 2019.
Dr. Plant previously held various global research and development (R&D) leadership positions within crop protection companies Bayer and Syngenta, as well as Merck Animal Health. Dr. Plant brings more than 27 years of international experience, covering all aspects of agrochemical active ingredient and end use product research and development. His strategic thinking, extensive knowledge and experience will help guide AgriMetis in new and exciting directions.
Steven Tuttle, President and CEO of AgriMetis states, “We’re extremely pleased that Andrew has joined our team. His experience, leadership and technical expertise will allow our organization to continue to discover, develop and deliver new innovative crop protection products to the global agricultural market. We’ve been impressed with Andrew’s R&D execution that is required in the agrichemical industry and we look forward to his contributions.”
Dr. Plant said, “I am very excited about joining AgriMetis, a company staffed with incredibly talented and dynamic people, driven by a desire to bring innovative products into the hands of growers, through a pioneering approach to agrochemical R&D.”
About AgriMetis: AgriMetis is committed to working with leading agriculture companies and businesses to fill the emerging need for sustainable crop protection products through leading edge and advanced discovery, development and delivery methods. The AgriMetis technology platform is at the interface of biology, biochemistry, and chemistry, employing a multidisciplinary and integrated scientific approach, allowing access to areas of chemical space and production routes that are inaccessible to others. AgriMetis was formed in March 2014 and completed a Series B financing in December 2016 to fund agriculture chemical research and development by applying a biopharmaceutical model. With headquarters near Baltimore, Maryland, AgriMetis continues to grow and develop its technologies and capabilities. For more information, please visit http://www.agrimetis.com.
This press release contains “forward-looking statements” concerning the development and commercialization of AgriMetis products, the potential benefits and attributes of such products, and company expectations regarding prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. AgriMetis undertakes no obligation to update any forward-looking statements for any reason.
